


In the claims:


Please amend the claims as shown:

1. (cancelled)


2. (currently amended) A The crystalline form of the compound of the free
~~base according to Claim 1, a pharmaceutically acceptable salt thereof or a solvate thereof,~~
~~wherein the compound of formula (I) is represented by a compound of the following formula~~
(II):



~~a compound of the following formula (III):~~



or a compound of the following formula (IV):



the crystalline form which is selected from crystalline free base of the compound of the formula II, crystalline hydrochloride salt of the compound of the formula II and crystalline ethanol solvate of methanesulfonate salt of the compound of the formula II.

3. (cancelled)

4. (cancelled)

5. (cancelled)

6. (cancelled)

7. (cancelled)

8. (cancelled)


9. (currently amended) A pharmaceutical composition comprising as an active ingredient the crystalline form of the compound of formula II ~~free base of formula (I)~~ according to Claim 2, ~~a pharmaceutically acceptable salt thereof, or a solvate thereof~~, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the composition.

10. (currently amended) An anti-tumor agent comprising as an active ingredient the crystalline form of the compound of formula II ~~free base of formula (I)~~ according to Claim ~~2,1~~, ~~a pharmaceutically acceptable salt thereof, or a solvate thereof~~, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the anti-tumor agent.

11. (cancelled)

12. (cancelled)

13. (new) A crystalline form of a compound of the following formula (III):




the crystalline form which is the crystalline hydrochloride salt of the compound of the formula III.

14. (new) A pharmaceutical composition comprising as an active ingredient the crystalline form of the compound of formula III according to Claim 13, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the composition.

15. (new) An anti-tumor agent comprising as an active ingredient the crystalline form of the compound of formula III according to Claim 13, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the anti-tumor agent.

16. (new) A crystalline form of a compound of the following formula (IV):



the crystalline form which is selected from crystalline free base of the compound of the formula IV and crystalline hydrochloride salt of the compound of the formula IV.

17. (new) A pharmaceutical composition comprising as an active ingredient the crystalline form of the compound of formula IV according to Claim 16, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the composition.

18. (new) An anti-tumor agent comprising as an active ingredient the crystalline form of the compound of formula IV according to Claim 16, together with a pharmaceutically acceptable carrier or diluent, wherein the crystalline form is in a solid state in the anti-tumor agent.